Blog
RSS FeedPosted by Michael Wonder on 11 Sep 2015
PHARMAC request for proposals – supply of progestagen-only long-acting intrauterine systems
11 September 2015 - PHARMAC invites proposals for the supply of progestogen-only long-acting intrauterine systems in New Zealand. ...
Posted by Michael Wonder on 09 Sep 2015
PHARMAC decision relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin)
9 September 2015 - The PHARMAC Board has approved the proposal relating to the funding of the TNF-inhibitor medicines adalimumab (Humira) ...
Posted by Michael Wonder on 31 Aug 2015
New Zealand Pharmaceutical Schedule - 1 September 2015
1 September 2015 - The September 2015 issue of the New Zealand Pharmaceutical Schedule is out and now in effect. There are ...
Posted by Michael Wonder on 30 Aug 2015
PHARMAC exceptional circumstances framework ‘go-live’ notification
31 August 2015 - PHARMAC is pleased to announce that its new Exceptional Circumstances Framework has now been implemented. The Exceptional ...
Posted by Michael Wonder on 19 Aug 2015
Responses to feedback on PHARMAC's proposed approach to market share procurement of hospital medical devices
19 August 2015 - PHARMAC sought feedback on our proposed approach to market share procurement (MSP) for hospital medical devices in ...
Posted by Michael Wonder on 05 Aug 2015
New Zealand Pharmaceutical Schedule - 1 August 2015 update
The August 2015 issue of the New Zealand Pharmaceutical Schedule is out and now in effect. The schedule includes the following new ...
Posted by Michael Wonder on 05 Aug 2015
Proposal to remove ‘stat’ dispensing from various pharmaceuticals not proceeding
PHARMAC would like to advise all interested parties that we will not be progressing a proposal to remove the ‘three ...
Posted by Michael Wonder on 05 Aug 2015
Woman's death during drug trial questioned
The Solicitor-General is considering whether to re-open a coroner's examination of the death of a woman while she was on ...
Posted by Michael Wonder on 05 Aug 2015
We want to hear from you
PHARMAC is giving you the opportunity to tell us how they're doing, what it’s like to work with them and what they can do ...
Posted by Michael Wonder on 05 Aug 2015
Haemophilia treatments funding proposal
PHARMAC is seeking feedback on a proposal involving the funding of haemophilia treatments. The treatments include recombinant factor VIII (rFVIII), ...
Posted by Michael Wonder on 05 Aug 2015
PHARMAC secures significant savings for DHBs on biologic drug
A new agreement for a high cost biologic drug will yield considerable savings for DHBs over the next five years, ...
Posted by Michael Wonder on 05 Aug 2015
PHARMAC decision to fund azacitidine and lenalidomide
PHARMAC is pleased to announce the approval of a proposal for azacitidine (Vidaza), lenalidomide (Revlimid) and thalidomide (Thalomid) that was ...
Posted by Michael Wonder on 05 Aug 2015
Proposal to list Nitrolingual Pump Spray (glyceryl trinitrate oral spray) and Azamun (azathioprine tablets)
PHARMAC is seeking feedback on a proposal relating to a provisional agreement with Douglas Pharmaceuticals Limited for the supply of ...
Posted by Michael Wonder on 05 Aug 2015
PHARMAC decision criteria review: final decision
PHARMAC has completed the review and are pleased to present the outcome, which is a new framework for PHARMAC’s decision-making. ...
Posted by Michael Wonder on 05 Aug 2015
Funding of abiraterone and other products supplied by Janssen
PHARMAC is pleased to announce the approval of a proposal for abiraterone acetate (Zytiga), methylphenidate hydrochloride extended release (Concerta), topiramate ...